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Abstract: [VO(acac)2] is a remarkable vanadium compound
and has potential as a therapeutic drug. It is important to
clarify how it is transported in blood, but the reports ad-
dressing its binding to serum proteins have been contradic-
tory. We use several spectroscopic and mass spectrometric
techniques (ESI and MALDI-TOF), small-angle X-ray scattering
and size exclusion chromatography (SEC) to characterize sol-
utions containing [VO(acac)2] and either human serum apo-
transferrin (apoHTF) or albumin (HSA). DFT and modeling
protein calculations are carried out to disclose the type of
binding to apoHTF. The measured circular dichroism spectra,
SEC and MALDI-TOF data clearly prove that at least two VO–
acac moieties may bind to apoHTF, most probably forming
[VIVO(acac)(apoHTF)] complexes with residues of the HTF
binding sites. No indication of binding of [VO(acac)2] to HSA
is obtained. We conclude that VIVO–acac species may be
transported in blood by transferrin. At very low complex
concentrations speciation calculations suggest that [(VO)(a-
poHTF)] species form.
1. Introduction
Bis(acetylacetonato)oxidovanadium(IV), or [VIVO(acac)2 (1), is
one of the most remarkable vanadium compounds. In the
solid state it consists of discrete molecules of [VIVO(acac)2 in
which vanadium(IV) presents an almost square pyramidal ge-
ometry (Figure 1).[1] It forms quite stable VIVO-complexes,[2, 3]
the reported stability constants in aqueous solution being log
b1 = 8.73 and log b2 = 16.27, respectively.
[4]
[VIVO(acac)2] has found uses in multiple areas. Namely, it has
been used as the vanadium precursor for the preparation of
many vanadium complexes where one[5–7] or both[8, 9] acac@ li-
gands are replaced.[10] It has also been used directly as catalyst
precursor in organic chemistry, for example, in aerobic oxida-
tions,[10, 11] epoxidations (e.g. of allylic alcohols, geraniol), sulfox-
idations[12] in combination with tert-butylhydroperoxide or
H2O2,
[13, 14] or immobilized in solid supports.[15]
[VIVO(acac)2] exerts interesting biological effects ; namely it
exhibits insulin-enhancing properties, in that in can stimulate
the phosphorylation of protein kinase B (PKB/Akt) and glyco-
gen synthase kinase-3 (GSK3).[16] It has also been shown to in-
hibit tyrosine phosphatases (PTPases), such as PTP1B.[16] The ef-
fects of [VIVO(acac)2] , [V
IVO(Et-acac)2] and of a few other V
IVO-
compounds on the glycemia of streptozotocin-induced diabet-
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ic rats (STZ-rats) were examined.[17, 18] [VIVO(acac)2] was also re-
ported to have antiproliferative effects[2, 19–21] and to have po-
tential as both antidiabetic and antipancreatic cancer agent to
prevent or treat patients suffering from both diseases.[19]
Another property of [VIVO(acac)2] is its remarkable activity in
degrading plasmid DNA in the absence of any activating
agents, air and photoirradiation.[20, 21] The nature of the pH
buffer was found to be determinant in the nuclease activity,
and in phosphate-buffered medium single-strand cleavage is
clear for concentrations of 1 as low as 1.2 mm (corresponding
to a ri = 0.08), and in the presence of activators it is much
more extensive.[20, 21] The mechanism is oxidative and mainly
associated with the formation of reactive oxygen species
(ROS).[21] Hydrolytic cleavage of the phosphodiester bond is
also promoted by 1, but at much slower rate, not competing
with the oxidative mechanism.[20] These properties may have
important implications in the interpretation of the biological
activity of [VIVO(acac)2] .
[VIVO(acac)2] thus exhibits insulin-enhancing properties and
several other relevant biological effects.[2, 16, 22, 23, 24] Since human
serum albumin (HSA) serves as a drug transport carrier and
human serum transferrin (HTF) is an important metal ion blood
carrier, the understanding of the interactions that may be es-
tablished between [VIVO(acac)2] and these plasma proteins is of
major importance to understand its pharmacokinetics and
pharmacodynamics. Additionally, most proposals explaining
the insulin-enhancing properties of vanadium compounds in-
volve formation of protein-vanadium complexes, namely in
blood,[21] thus, the understanding of the speciation of
[VIVO(acac)2] in blood and how this might be important in the
uptake of vanadium by cells, are relevant issues.
Regarding the transport of vanadium compounds in blood
in vivo, most studies agree that these are predominantly trans-
ported bound to serum proteins, particularly HTF.[24–32] More re-
cently the uptake of V-species by red blood cells (RBCs) and its
possible role was highlighted,[33–35] but at the low total vanadi-
um concentrations expected in vivo in the blood following
oral administration of V antidiabetics, most probably signifi-
cantly less than ca. 20 mm even upon oral treatment with
a VC,[30, 36] HTF appears to be the main vanadium transporter
and RBCs possibly play some role in the pharmacokinetics of
these compounds and in providing a reducing effect, eventual-
ly allowing the formation of VIII, which may strongly bind to
HTF.[37]
The binding of [VIVO(acac)2] to albumin was studied by EPR
and ENDOR spectroscopies,[38] and Mustafi et al.[39] used iso-
thermal titration calorimetry (ITC) and spectrofluorometry to
determine the binding constant of [VIVO(acac)2] to bovine
serum albumin (BSA). It was reported that glucose uptake by
3T3-L1 adipocytes was significantly higher when using
[VIVO(acac)2] in the presence of HSA (when the albumin:
[VIVO(acac)2] ratio+1.0).[2, 38] These authors also stated that
serum albumin enhanced the insulin-like activity of all studied
V-complexes, including 1, more than human serum transfer-
rin,[40] and that the characteristics described are related to the
high stability and capacity of [VIVO(acac)2] to remain intact
upon binding to HSA. Moreover, the specificity of 1 for highly
glycolytic cells, its low toxicity[25] and its anti-tumorigenic prop-
erties[23, 24, 41, 42] contribute to make 1 a potentially useful con-
trast agent for early tumor detection, and possibly also for
treatment. The advantage of [VIVO(acac)2] for this purpose
would result from its binding to serum albumin increasing its
serum half-life and allowing its transport and delivery to its tar-
geted tumor site.[39]
Garribba and co-workers[27, 29, 43–45] studied extensively the
binding of VIVO-complexes to blood components, mainly by
using EPR spectroscopy. Namely, the anisotropic EPR spectra of
solutions containing VIVO2 +-HTF, VIVO2 +-acac, VIVO2 +-apoHTF-
acac and VIVO2+-holoHTF-acac, in the presence and absence of
other blood serum components, were recorded at pH 7.4.
Globally the authors report that two different species could be
distinguished, one in higher concentration, identified as
(VIVO)2apoHTF, and the 2
nd one as [VIVO(acac)2] , and no V
IVO-
acac-apoHTF species were identified. These authors further
stated that the EPR spectroscopic data suggest that no mixed
complexes are formed, this being in agreement with acetyla-
cetonate not acting as a synergistic anion.[29, 45] In similar stud-
ies with HSA, the authors report that only [VIVO(acac)2] is de-
tected, and that the EPR spectra of solutions containing
[VIVO(acac)2] and 1-methylimidazole are practically indistin-
guishable from those of the binary system VIVO2 +-acac,[29] no
VIVO-acac-HSA species being identified.[29, 44] Similar conclusions
were made from the measurement of the anisotropic EPR
spectra of solutions containing [VIVO(acac)2] and holoHTF: no
[VIVO(acac)2(holoHTF)] species were detected,
[45] and again it
was considered that [VIVO(acac)2] has a square-pyramidal coor-
dination geometry and has no tendency to form complexes of
the type cis-[VIVO(carrier)2(protein)] , this being allegedly corro-
Figure 1. Structural formulae of [VIVO(acac)2] (1) (left). In [V
IVO(acac)2(L)] complexes, the donor atom of ligand L may bind trans or cis to the O-oxido. If the
binding is trans, also often called the axial position, no particular rearrangement of the two acac@ ligands is required; if the binding is cis, also often called
the equatorial position, one of the acac@ ligands will then have one of its O-atoms bound trans to the O-oxido ligand (as in [VIVO(acac)2(Phpy)] , Figure 2).
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borated by the conclusion that no ternary species are formed
by VIVO2 + , acetylacetonate and 1-methylmidazole. Similar con-
clusions were made by the same group in studies with Immu-
noglobulin G.[43]
Notwithstanding, contradicting the initial statements of
Selbin,[46] [VIVO(acac)2] is a weak Lewis acid, and for example,
upon dissolution in organic solvents or in solutions containing
potential ligands, the vanadium may coordinate a donor
ligand in the vacant site, forming complexes expressed as
[VO(acac)2(L)] , sometimes designated as adducts, with for ex-
ample, amide, amine, sulfoxide and pyridine solvents/ligands,[3]
and this process [Eq. (1)] has been studied by several meth-
ods.[3, 47, 48–54]
½VIVOðacacÞ2Aþ LÐ ½VIVOðacacÞ2ðLÞA ð1Þ
In earlier work, solvent effects were explained by coordina-
tion to the vacant axial position, but this was later questioned
in several publications[3] and the available literature is not
always in agreement. In fact, in solution, while some authors
state that [VIVO(acac)2] bind solvents in trans position,
[49, 50] sev-
eral studies also showed that some solvents bind to the VIV
equatorially, and other publications report either cis- or trans-
binding depending on the ligand added.[51–53] With some sol-
vents, the interaction (e.g. hydrogen bonding) with the O-
oxido ligand has also been proposed.[55–58] For example, IR
studies with pyridine derivatives demonstrated the existence
of adducts with the sixth ligand bound cis rather than trans to
the oxido O-atom (Figure 1),[52, 54] and ENDOR studies showed
that while for example, methanol binds to the vacant axial
6th position, it was shown that either cis or trans isomers are
formed with some substituted pyridines.[51] In fact, although
this may result from solid state effects, a single crystal X-ray
diffraction (XRD) study of the 4-phenylpyridine (Phpy) adduct 3
confirmed the possibility of cis binding of substituted pyridines
(Figure 2).[59] On the other hand, the structure determined by
single crystal XRD of [VIVO(acac)2(4-methylpyridine)] consists of
discrete molecules with 4-methylpyridine in the trans position
and short V = O (1.557 a) and long V-N (2.447 a) bond
lengths.[60] In the adduct formed with dioxan,
[VIVO(acac)2(dioxan)] ,
[61] the dioxan bridges two [VIVO(acac)2]
molecules axially (trans) to the V centers ; in [VIVO(acac)2(2-pyri-
done)] the 2-pyridone is bound axially,[62] as pyrazole (Pz) in
[VIVO(acac)2(Hpz)] (2).
[63]
Overall, taking into account the literature data, the interac-
tion of ligands (solvent or a dissolved molecule) with
[VIVO(acac)2] may involve:
[3] (i) coordination in a sixth position
trans to the oxido O-atom, (ii) coordination in a sixth position
cis to the oxido O-atom, and (iii) hydrogen bonding to the O-
oxido or atoms of the ligand (e.g. with chloroform[51, 56]).
HTF has 8 tryptophan residues (3 in the N-lobe, 5 in the C-
lobe) and 25 tyrosines (14 in the N-lobe, 12 in the C-lobe).[64]
The two iron binding sites are located near the junction of two
domains formed by Cys-117 to Cys-194 bond in the N-termi-
nus. Potential amino acid residues that may act as ligands for
VIV in the iron binding sites are Tyr188, Tyr95, His249 and
Asp63 (N-lobe) and Tyr426, Tyr517, His585 and Asp392 (C-
lobe). Side groups of other residues of HTF may bind VIV,
namely imidazole donors from histidines, and His-14, His-289,
His-349, His-350, His-473, His-606 and His-642 have been con-
sidered as good candidates.[45] The structure of human serum
albumin consists of a single polypeptide chain with 585 amino
acid residues, with a 3-dimensional structure normally de-
scribed in terms of 3 homologous chains (I, II and III), each of
them formed by two subdomains (A and B). HSA has one tryp-
tophan residue (Trp214 located in subdomain II-A) and 18 tyro-
sine residues.
As described above, there are many reports on in vitro and
in vivo experiments proving several relevant biological effects
of [VIVO(acac)2] . It has been repeatedly emphasized
[2, 4, 45, 65] that
[VIVO(acac)2] is a stable entity. However, there are also many
studies confirming the formation of mixed-ligand complexes
[VIVO(acac)2(L)] or [V
IVO(acac)(L1)(L2)(L3)] . Therefore, the forma-
tion of such complexes where L1, L2 and L3 could be donor
atoms from HTF (or HSA) appears plausible. The binding to
HTF could involve some of the donor atoms of the Fe-binding
site, or donor atoms of side groups of other amino acid resi-
dues. This reasoning and the contradictory reports of the
groups of Garribba and Makinen, regarding the binding of
[VIVO(acac)2] to HSA (and apoHTF), and the conclusion of Gar-
ribba and co-workers that cis-[VIVO(acac)2(protein)] or
[VIVO(acac)(protein)] do not form with serum proteins, mainly
based on EPR spectroscopic measurements, when there are
many other papers confirming the formation of [VIVO(acac)2(L)]
and [VIVO(acac)(L)] compounds, made us study the systems
VIVO-acac-HTF and VIVO-acac-HSA using several dis-
tinct experimental techniques to clearly prove if VIVO-
acac species can bind these proteins or not.
2. Results and Discussion
2.1. [VIVO(acac)2] in aqueous solution.
2.1.1. UV/Vis absorption studies.
In aqueous solutions of [VIVO(acac)2] Crans and co-
workers[17, 65] reported the observation of three spe-
cies by EPR spectroscopic measurements at room
temperature whose concentrations were time, pH,
temperature and salt dependent. The three com-
Figure 2. Structural formulae of two [VIVO(acac)2] adducts characterized by single crystal
X-ray diffraction: [VIVO(acac)2(pyrazole)] (2)
[43] and [VIVO(acac)2(Phpy)] (3).
[59]
Chem. Asian J. 2017, 12, 2062 – 2084 www.chemasianj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim2064
Full Paper
plexes were assigned as the trans-[VIVO(acac)2(H2O)] , cis-
[VIVO(acac)2(H2O)] and a V
IVO-hydrolysis product containing one
acac@ ligand. No evidence for VV was found in fresh solutions
of [VIVO(acac)2] , but slow oxidation occurs.
[17] The speciation di-
agram depicted in Figure 3 shows that in the system VIVO2 + +
acac around the physiological pH VIVO is mostly present as the
neutral complex [VIVO(acac)2] , the hydrolysis degree being low.
At pH&3.3 [VIVO(acac)+] species predominate, while for pH<
2.0 [VIVO(H2O)5
2 +] is the predominant VIVO-complex.
Mustafi et al and Makinen et al.[2, 38, 58] provided a distinct spe-
ciation diagram where [VIVO(acac)2] is considered stable in
aqueous solutions of pH 2. However, this contradicts other ob-
servations,[4, 17] considered compatible with the formation of
[VIVO(H2O)5
2+]![VIVO(acac)+]![VIVO(acac)2] as the pH is in-
creased. In the SI section we discuss why we consider Figure 3
to correspond to the correct speciation, also demonstrating
that [VIVO(acac)2] is not stable in aqueous solutions of pH 2.
As mentioned above, there are several studies in the litera-
ture reporting the coordinative binding of amines and of other
monodentate ligands to [VIVO(acac)2] in solution, namely in-
cluding the determination of binding constants K [Eqs. (1) and
(2)] .[47, 48]
K ¼ ½VOðacacÞ2ðLÞA½VOðacacÞ2A½LA ð2Þ
Most of these studies were done by electronic absorption
measurements in organic solvents (e.g. benzene, nitrobenzene,
dichloromethane) ; for example, for pyridine the values deter-
mined in CH2Cl2 and benzene were 867:53[48] and 56:5,[47]
respectively. The value of K obviously also depends on the
amine considered; for example, for piperidine and pyrrolidine,
the values determined in benzene were 1400:400 and
2900:1000,[47] respectively. In aqueous media the K values will
certainly differ from these, and the degree of formation of the
adducts [VIVO(acac)2(L)] will also depend on the pH of the solu-
tion and pKa of the amine.
We measured the spectra of aqueous solutions containing
[VIVO(acac)2] and several potentially monodentate ligands (see
experimental and SI sections for details): imidazole, 2-Me-imi-
dazole, benzimidazole, pyrazole, 4-t-buthylphenol at pH 7.0:
0.2. Considering the speciation diagram of the VIVO-acac
system with CVO = 2 mm and Cacac = 4 mm (Figure 3), in the pH
range ca. 6.2–7.2 the amount of [VIVO(acac)2] is maximized,
while maintaining its hydrolysis at a reasonable low level (less
than ca. 5 % of total vanadium). Figure 4 depicts data for imi-
dazole and pyrazole. The absorption spectra of these solutions
were measured in the range 380–900 nm, each measurement
starting always after the same period of time upon adding the
required amount of the [VIVO(acac)2] solution (in MeOH) to the
aqueous solution containing the buffered solution of the
ligand L. The additions of imidazole, 2-Me-imidazole, or pyra-
zole to the [VIVO(acac)2] solutions all yielded an increase in the
absorbance values in the range 380–900 nm. This effect is
clearly observable at a L:[VIVO(acac)2] ratio of 1:1, but larger
amounts of ligand present in the final solution almost did not
cause further increase; because no significant shift of the ab-
sorption maxima is seen in these visible absorption spectra
probably the interaction is weak.
Figure 3. Speciation diagram calculated for total VIVO and acetylacetone
concentrations of 2 and 4 mm, respectively, considering the formation con-
stants log b1 = 8.73 and log b2 = 16.27, reported in [4] and the V
IVO-hydrolyt-




refs. [3, 25] .
Figure 4. Absorption spectra of solutions of [VIVO(acac)2] added to solutions of (A) imidazole (Im), and (B) pyrazole (Pz) containing a 40 mm carbonate buffer.
The maximum amount of methanol of the samples was ca. 3 %. The spectra recorded correspond to independent samples with a concentration of
[VIVO(acac)2] of 2.0 mm and pH 7.0:0.2. The L:[VIVO(acac)2] ratios are indicated.
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It is clear that, in the presence of imidazole (or 2-Me-imida-
zole or pyrazole), a significant global increase in the e values in
the 380–900 nm range takes place, which can only be ex-
plained by the binding of the N(3) atom of imidazole (or N-
atoms of 2-Me-imidazole or pyrazole) to [VIVO(acac)2] . It may
be observed that for Im:[VIVO(acac)2] ratios of 1:2 or 1:4 the
spectra do not differ much from the one recorded at a 1:1
ratio, this meaning that at this ratio most of the imidazole was
already bound to [VIVO(acac)2] . The possibility of non-coordi-
nating interactions explaining the increase in absorption
values cannot be ruled out. However, the change in the spec-
tra observed is similar to those observed in the monodentate
binding of O-carboxylate of several hydroxycarboxylic acids[66]
and amino acids,[67–73] where the monodentate coordinative
binding was demonstrated by several spectroscopic methods
and pH-potentiometric titrations.
To further prove the possibility of monodentate binding of
these monodentate ligands to [VIVO(acac)2] , rather similar ex-
periments were carried out with l-lactic acid at pH&6.0; these
are described in the SI section (SI-8.4). Figure SI-8.4-1 depicts
absorption spectra of some of these solutions and Figure SI-
8.42 the CD spectra. There are some subtle changes in the ab-
sorption spectra of the solutions at lmax&560 and 820 nm akin
to those observed in the similar experiments described above
(e.g. Figure 4). Importantly, weak but clearly measurable CD
spectra were recorded with the same samples which
can only be explained by the coordinative monoden-
tate binding of the O-carboxylate to [VIVO(acac)2] . If this
corresponded to bidentate binding the absorption
spectra would certainly have distinct lmax from those of
[VIVO(acac)2] , and that is not the case. Establishment of
hydrogen bonding of the O-hydroxyl of lactate to the
O-oxido or to O-acac atoms cannot be ruled out.
The additions of benzimidazole and of 4-tert-butyl-
phenol were examples where this effect of absorption
increase did not depict a clear trend (see SI section). In
the case of benzimidazole possibly because of steric
hindrance; in the case of 4-tert-butylphenol probably
also because of its relatively high pKa value (10.2), thus
at pH 7.0 the phenolic OH remains protonated and its
propensity to bind [VIVO(acac)2] is low.
2.1.2. Mass spectrometric studies.
To further confirm the formation of [VIVO(acac)2(L)] spe-
cies in aqueous media, solutions of the same potentially
monodentate ligands: imidazole, methylimidazole, ben-
zimidazole, pyrazole and phenol (this instead of 4-tert-
butylphenol) were prepared in 10 mm NH4CH3COO
aqueous solution (previously set to pH 6.5). Accurately
measured volumes of each of these solutions and of
the NH4CH3COO aqueous solution were added to six
distinct vials, and accurately measured volumes of
[VIVO(acac)2] in methanol (80 mm) was added to each of
the six vials. Final solutions were 1.1 mm in [VIVO(acac)2]
and 2 % v/v MeOH, and the molar ratios ligand:VIVO
was 7:1 in all samples; pH values ranged from 6.58 to 7.15.
For each of the six solutions, ESI-MS (+ /-) was carried out
ca. 5–10 minutes after the addition of [VIVO(acac)2] ; samples of
these solutions were also taken for EPR spectroscopic measure-
ments and immediately frozen in liquid N2 (see below). The
ESI-MS of the solution containing only [VIVO(acac)2] differed sig-
nificantly from those of [VIVO(acac)2] and monodentate ligands.
The results of these experiments are described in the SI section
and the data is summarized in Table 1. Globally the mass spec-
trometric data confirm the formation of [VIVO(acac)2(L)] species
in aqueous media for L = imidazole, methylimidazole, benzimi-
dazole and pyrazole. Only in the case of L = phenol no assign-
ments could be made confirming the formation of
[VIVO(acac)2(phenolato)] in the conditions used.
2.1.3. EPR spectroscopy studies.
With the solutions prepared for the MS experiments men-
tioned in the previous section, samples were collected for EPR
spectroscopic measurements. The results are described in the
SI-section. All measured EPR spectra for aqueous solutions at
pH ca. 6.6–7.1 of [VIVO(acac)2] and of [V
IVO(acac)2] + L (L = imi-
dazole, methylimidazole, benzimidazole, pyrazole and phenol)
and almost superimposable, thus it is plausible that the inter-
action of these ligands with [VIVO(acac)2] is axial. Figure SI-8.3-
Table 1. Summary of assignments in ESI-MS experiments with solutions of
[VIVO(acac)2] upon addition to solutions of several potential monodentate ligands.
a
System and tentative assignment Mass ob-
served


















[VIVO(acac)2 + MeOH + H]
+ (+) 297.9 [VIVO(acac)(Im)2]
+ (+) 301.9











[VIVO(acac)2(MeIm) + H2O + H]
+ (@)
317.91




+ (+) 384.3 [VIVO(acac)(Pz)]+ (+)
231.14
[VIVO(acac)2(MeIm) + H2O + Na
+]+ (+)
401.91
[VIVO(acac) + 2(Pz)]+ (+)302.00











[VIVO(acac)2(Bz) + H2O + H]
+ (+)
401.91
[a] Although during the ESI process free ligands may bind non-specifically to
[VIVO(acac)2] , resulting in false positives,
[74, 75] we explain our our data considering
coordinative binding. Non-coordinative binding is much more probable with sol-
vent or buffer molecules, present in much higher amounts.
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25 depicts the low field range of these spectra. Thus, although
the visible absorption and mass spectrometric measurements
indicate the formation of [VIVO(acac)2(L)] complexes in aqueous
solution, the EPR spectra of all systems measured are almost
equal and superimposable with the EPR spectrum of
[VIVO(acac)2] .
2.2. Interaction of [VIVO(acac)2] with human serum transfer-
rin
2.2.1. Circular dichroism
In the visible range, because the protein does not absorb, only
charge transfer or VIVO-d-d electronic transitions are observed.
Thus, clearly measurable De values can only be recorded in the
visible range of the circular dichroism (CD) spectra when there
is coordination of donor atoms of the protein to vanadium(IV) ;
otherwise no induced CD-bands due to charge transfer or d-d
transitions can be measured.[31, 67, 76, 77]
The type of spectrum obtained for VIVO-compounds in the
visible range depends on the particular binding and environ-
ment of the chiral donors around the VIVO center. If more than
one chiral VIVO-complex forms in solution, the measured CD
spectrum is the weighted sum of the CD spectra of all VIVO-
complexes formed in the system being studied, each corre-
sponding to a set of distinct De(l) values (see SI-section).
Figure 5 includes CD spectra in the 400–1000 nm range of sol-
utions containing apoHTF and VIVOSO4 (blue lines). It is known
and accepted[26, 27, 29, 31, 34, 64, 68, 78] that in such solutions the VIVO2 +
is bound by donor atoms of residues of the iron binding site
of HTF, forming either 1:1 or 2:1 (VIVO:apoHTF ratio) com-
plexes.
The fact that non-zero De values are measured in the visible
range for solutions containing [VIVO(acac)2] and apoHTF
(Figure 5) and that the pattern of CD spectra obtained differs
from those of solutions containing VIVOSO4 and apoHTF (con-
taining (VIVO)nHTF complexes), means that:
(i) significant amounts of VIVO-acac species bind to HTF and
(ii) there is no extensive hydrolysis of the VIVO-acac species
leading to the formation of (VIVO)nHTF complexes.
It is also noteworthy that the order of magnitude of the
measured De values for the system [VIVO(acac)2] and apoHTF is
the same as those measured for solutions containing
(VIVO)nHTF complexes. From the CD spectra shown in Figure 5
it cannot be concluded with certainty what type of VIVO-acac-
HTF complexes are formed, but the relatively high De values
measured suggests that a significant fraction of these com-
plexes correspond to [VIVO(acac)(HTF)] species, where the
VIVO:acac molar ratio is 1:1, and the VIV is bound to more than
one chiral residue of apoHTF,[26] as otherwise the De values
would be significantly lower, as was the case of those mea-
sured in solutions containing [VIVO(picolinato)2] and lyso-
zyme,[79] or in solutions containing VIVO2 + and amino acids
with monodentate coordination of the a-COO@ moiety to
VIV.[67–72]
At least two distinct types of CD spectra may be distinguish-
ed in Figure 5, this also corresponding to at least two distinct
VIVO-acac complexes. In fact, in the spectrum of the solution
with the [VIVO(acac)2]:apoHTF molar ratio of 1:0.5 (black line)
the De values are <0 in the range 700–1000 nm (band I), cor-
responding to transitions dxy!dxz,dyz (both dxz and dyz have
similar energy)[3] while for higher molar ratios two distinct
bands (corresponding to dxy!dxz and dxy!dyz, often designat-
ed by bands IA and IB) are clearly observed, the De values pro-
gressively increasing and becoming >0 for l>&930 nm as
the [VIVO(acac)2]:apoHTF molar ratio increases. The two distinct
patterns of the CD spectra measured imply that two different
types of chiral VIVO-acac-apoHTF species form as [VIVO(acac)2] is
added. It is also noteworthy that the addition of one more
mole equivalent of [VIVO(acac)2] to the solution with
[VIVO(acac)2]:apoHTF molar ratio of 3 does not produce signifi-
cant changes in the CD spectra measured. Thus, if more than
two VIVO-acac species bind to apoHTF, this is not clearly visible
in the CD spectra measured.
2.2.2. Small-angle X-ray scattering (SAXS).
Data from native apo-transferrin were evaluated for concentra-
tion dependence using Primus,[80] and extrapolated to zero
concentration. Using this method, a radius of gyration of
33.2 a was derived from the experimental data, with approxi-
mate molecular weight of 74 kDa, and Porod volume
137 000 a3. This is in agreement with the known molecular
weight of &79 kDa. The Kratky plot indicates a globular, multi-
domain protein, as expected from the published PDB struc-
tures. The P(r) function derived from the data indicates Dmax
(the maximum atomic distance vector in the system) to be
112 a as shown in Figure SI-9-1. Shape reconstruction using
the data pipeline described in the SI section was carried out,
with the filtered and refined structures shown in Figure SI-9-2.
The data indicates interesting differences between the solution
state structure and that derived from X-ray crystallography.
Using the PDB model 2HAV,[81] a theoretical Rg (radius of gyra-
tion) of 31 a was obtained using the CRYSOL package.[82] The
Figure 5. Circular dichroism spectra in the visible range of solutions contain-
ing apoHTF (&600 mm) and [VIVO(acac)2] , and of VIVOSO4 and apoHTF
(&750 mm) at pH 7.4, with the indicated VIV:apoHTF molar ratios. The base-
line in this Figure corresponds to the CD spectrum of the solution of
apoHTF. A quartz cell with optical path of 2.0 cm was used.
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theoretical fit, shown in Figure SI-9-3, is satisfactory, suggesting
that, despite the described Rg difference, the overall envelope
shape of the solution state and crystallographic structure is
similar.
A similar methodology was followed for the apoHTF-
[VIVO(acac)2] sample. Comparing the results obtained from
both samples, the sample containing apoHTF and [VIVO(acac)2]
showed immediate, detectable differences on the SAXS length
scales (Figure SI-9-4). In particular, the incubated sample was
shown to possess significantly smaller radius of gyration at
30.8 a, and smaller derived molecular weight, at 66 kDa. More-
over, even if the indicated globular structure is conserved, the
normalized Kratky plot appears to indicate significant differen-
ces in domain structure from the native apoHTF. Not surpris-
ingly, there is also a significant difference in the P(r) function
between the native and the incubated sample (Figure 6) with
the concomitant discrepancy in Dmax values (112 a and 104 a,
respectively). A shape reconstruction is shown in Figure SI-9-6.
Therefore, the analysis of the SAXS data strongly suggests
a clear modification on the conformation of apoHTF upon
[VIVO(acac)2] binding, suggesting the existence of relatively
strong protein-complex interactions.
2.2.3. Maldi-TOF Mass spectrometric data.
As described in the experimental section the samples for
MALDI-TOF MS were prepared with apoHTF:[VIVO(acac)2] molar
ratios of 1:0, 1:1, 1:2, 1:3 and 1:5 by mixing different volumes
of the stock solutions with a NH4HCO3 buffer (pH 7.4, 25 mm).
The results hereby reported were obtained with samples pre-
pared by the Dried Droplet procedure, and each final spectrum
was the accumulated result of at least 1000 laser shots that
were obtained from 10 different manually selected regions of
the same sample, over the range 14 000–160 000 Da.
In a set of experiments, the average mass obtained for
apoHTF was 79 247(:20), while the average mass obtained
with samples containing 1:3 apoHTF:[VIVO(acac)2] molar ratios
was 79 581(:20). Thus, the difference in masses is significant
(&334). We assign this difference to the binding of two
[VIVO(acac)+] moieties to apoHTF, which corresponds to
&332 Da. Figure 7 depicts two representative Maldi-TOF mass
spectra.
In a distinct set of experiments the [VIVO(acac)2]:apoHTF
molar ratios were increased and the differences in masses
were 201 (for 1:1), 346 (for 2:1) and 346 (for 3:1), this agreeing
with the binding of one [VIVO(acac)+] moiety to apoHTF for
the 1:1 molar ratio, and two for the 2:1 and 3:1 molar ratios.
Interestingly, in similar MALDI-TOF experiments carried out
with 5:1 [VIVO(acac)2]:apoHTF molar ratios the obtained aver-
age difference in mass between the samples of apoHTF and
[VIVO(acac)2]:apoHTF was 653(:60, considering the several
spectra obtained for different samples of these solutions). This
is consistent with the binding to apoHTF of for example, two
[VIVO(acac)(H2O)
+] moieties + one [VIVO(acac)2] (total mass =
633).
By doing experiments (described in the experimental sec-
tion) doing laser shots in separate but very close spots, one
containing the apoHTF, the other containing the solution of
[VIVO(acac)2] , where the m/z peaks obtained were equal to
those of apoHTF alone, the existence of false positives can be
ruled out (or at least the probability of their existence consid-
ered extremely low). We cannot totally rule out the possibility
of non-covalent interactions explaining the increase in mass.
However, it should be highlighted that the peak shapes (of m/
z = 1 and 2) are both similar and sharp. If several different pro-
tein-complex interactions were established (as for non-covalent
interactions), this would lead to broadening of the peaks.[83]
Figure 6. Superposition of pair distance distribution function for both ana-
lyzed samples—native apoHTF (black) and apoHTF-[VIVO(acac)2] (reddish)—
highlighting their disparity.
Figure 7. MALDI-TOF mass spectra obtained for samples of (a) apoHTF and
(b) apoHTF + [VIVO(acac)2] (with 3:1 [V
IVO(acac)2]:apoHTF molar ratios).
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2.2.4. Use of size exclusion columns.
To further confirm the binding of [VIVO(acac)2] to transferrin,
solutions containing apoHTF (ca. 140 mm) and different
amounts of [VIVO(acac)2] were prepared, with molar ratios rang-
ing from 1 to 8, and eluted with a tris buffer solution through
desalting columns (PD-10 size exclusion columns, see experi-
mental and SI sections). When using these columns the frac-
tions first eluted contain apoHTF (and species bound to it),
while the small molecules not bound to the macromolecule
are retained inside the pores of the packing of the column,
and are only eluted after significantly larger volumes of buffer
pass through it. The eluate of the first eluted fractions were an-
alyzed by inductively coupled plasma—atomic absorption
spectroscopy (ICP-AES). The dilution effect from the elution
(&67 %) was determined taking into account the absorbance
of an apoHTF solution before and after eluting it, in experi-
ments with no addition of [VIVO(acac)2] . Results of the ICP-AES
analysis are included in Table 2. In this table, the similarly ob-
tained values for HSA are also included (see section 2.3.3).
From these experiments it is clear that the eluted apoHTF
fractions contain bound vanadium complexes. The vanadiu-
m:apoHTF molar ratios determined in these fractions (3rd
column of Table 2) are lower than those in the corresponding
solutions added to the top of the size exclusion columns, the
differences increasing with the increase in the initial
[VIVO(acac)2]:apoHTF molar ratios. In fact, for the 1.01:1 ratio
the difference between the ratios V:HTF in the added and
eluted solutions is &11 %, this meaning that the VIVO-complex
is quite strongly bound to apoHTF. For the 2.05:1 molar ratio,
ca. 73 % of vanadium remains bound to the protein, while for
the 7.89:1 molar ratio only ca. 39 % of total vanadium initially
added remained bound to apoHTF. This suggests that up to
a [VIVO(acac)2]:apoHTF molar ratio of ca. 2 the vanadium com-
plex binds quite tightly to the protein, while higher amounts
of VIVO-acac species do not bind so strongly. Thus the equilibri-
um:
Vanadium bound to apoHTF
Ð Vanadium ðnot bound to apoHTFÞ þ apoHTF ð3Þ
is, in proportion, more shifted to the right as the
[VIVO(acac)2]:apoHTF molar ratio of the solutions prepared in-
creases, this indicating that the “first” two moles of vanadium
bind to distinct sites (thus forming distinct and more tightly
bound complexes) from those that start being “occupied” only
when having higher molar ratios.
In these experiments, where the vanadium amount is deter-
mined by ICP-AES, no information may be obtained regarding
which VIVO-containing species bind to apoHTF. Notwithstand-
ing, the data obtained by mass spectroscopy are compatible
with those obtained with the size exclusion columns: a total of
at least three VIVO-moieties might bind to apoHTF. The mass
spectrometric data suggests that when taking excess of
[VIVO(acac)2] , two [V
IVO(acac)+] moieties may be bound to
apoHTF residues, for example, of the Fe binding sites, as well
as one [VIVO(acac)2] (more weakly bound). We cannot rule out
the possibility that the binding of VO-acac species to apoHTF
might be non-covalent, but the pattern of results obtained
and the fact that almost no binding was found for HSA indi-
cates that at least two VO-acac species bind to apoHTF involv-
ing coordinative bonds.
2.2.5. Electron Paramagnetic Resonance
Our present CD data clearly confirm that VIVO-acac-apoHTF
species do form in solutions containing [VIVO(acac)2] and
apoHTF, contradicting previous conclusions[29, 44] mainly based
on EPR spectroscopic measurements, where no VIVO-acac-
apoHTF species were identified. In studies with HSA[29, 38] and
with Immunoglobulin G[43] it was also reported that only
[VIVO(acac)2] (not bound to the proteins) is detected.
The EPR spectra for aqueous solutions of [VIVO(acac)2] depict
broad lines due to solute aggregation upon samples freezing.
Addition of &2 % of ethylene glycol favors glass formation and
well-resolved spectra are obtained. Several solutions of
[VIVO(acac)2] in this work were made in DMSO and later diluted
in buffers, the content of DMSO varying from 4 to 10 %; the
EPR spectra of frozen solutions of [VIVO(acac)2] containing 2 %
of ethylene glycol or 4–10 % of DMSO were identical. Figure SI-
4-1 depicts examples of these EPR spectra and Table 3 summa-
rizes the spin Hamiltonian parameters obtained. The spectra of
[VIVO(acac)2] in water was simulated considering either (i) axial
symmetry and the presence of 2 species; or (ii) rhombic sym-
metry considering only one species. Although both simulations
gave good fittings, the bandwidth in the low and high field re-
gions is quite large, suggesting that 2 species coexist (see Fig-
ures SI-4-2 to SI-4–5 and discussion in SI section). Therefore, in
Table 3 we consider the existence of two species. The spin
Table 2. [VIVO(acac)2]:apoHTF and [V
IVO(acac)2]:HSA molar ratios of the
solutions prepared and applied to the top of size exclusion columns, and





















1.01 0.8(4) V 10@4 0.9 89 %
2.05 1.4 V 10@4 1.5 73 %
4.02 1.9 V 10@4 2.1 52 %
7.89 2.9 V 10@4 3.1 39 %
HSA
2.0 <10 V 10@6 <0.2 <10 %
5.0 5.1 V 10@5 &0.5 &10 %
[a] The concentrations of vanadium in the first eluted fractions were de-
termined by ICP-AES. [b] The concentration of apoHTF and of HSA in the
eluted fractions was determined by UV absorption spectroscopy upon
eluting samples only containing the protein. In the case of apoHTF the
solutions applied on the top of the column were &140 mm and in the 1st
eluted fraction were &94 mm ; in the case of HSA they were 137.4 mm and
in the 1st eluted fraction were &96.1 mm.
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Hamiltonian parameters calculated theoretically using DFT
methods and considering either water or methanol as solvent
both yielded Az = 167.3 V 10
@4 cm@1, thus giving good agree-
ment with the experimental values obtained in this work or
with those of Garribba et al.[49] and other authors.[2, 51]
The EPR spectra of the solutions containing [VIVO(acac)2] and
apoHTF frozen ca. 10 min. and 24 h after preparation are iden-
tical (Figure SI-5-2). Figure SI-5-3 depicts X-band EPR spectra,
measured at 77 K, of a solution of [VIVO(acac)2] in water (con-
taining &10 % DMSO) and of solutions containing [VIVO(acac)2]
and apoHTF (2:1 and 4:1 molar ratios). Noteworthy is the ob-
servation that while the EPR spectra for solutions containing
[VIVO(acac)2]:apoHTF molar ratios of 4:1 (typically the condi-
tions used in the experiments of Garribba and co-workers[29, 44])
are almost identical to those of [VIVO(acac)2] , that of the
sample with 2:1 molar ratio differs significantly. This is empha-
sized in Figure 8, where an amplification of the high field
range of the same spectra is depicted. The species
designated by D (with gz = 1.949; Az = 171.5 V
10@4 cm@1) differs from those of [VIVO(acac)2] . It
resembles the spin Hamiltonian parameters of
the VIVO-apoHTF species B (Table 3), but the
corresponding CD spectra differ significantly, thus
species D should be assigned to a VIVO-acac-HTF
complex.
The spin Hamiltonian parameters determined for
solutions containing [VIVO(acac)2] in the presence or
absence of apoHTF are quite similar, but not identi-
cal ; they are also not much different from those ob-
tained for the VIVO-apoHTF system (Table 3). Regard-
ing the identification of the VIVO-acac-apoHTF spe-
cies that form, namely if either [VIVO(acac)2-apoHTF]
or [VIVO(acac)-apoHTF] species form, it is not possible
to indicate definite formulations from the EPR spec-
tra measured. In fact, although frozen solution EPR
spectra are an extremely useful tool to characterize
and distinguish distinct VIVO-species that may be
present in a certain medium,[84–89] EPR spectra of
frozen solutions may not be a totally reliable guide
for judging the molecular structure of VIVO-com-
plexes,[51, 84] particularly when several species may
form which yield similar spin-Hamiltonian parame-
ters, as is the case here (see also below).
The formation of [VIVO(acac)(apoHTF)] species is
akin of the formation of [VIVO(acac)(L)] compounds.
Such type of complexes have been often reported,
some of them with molecular structure characterized
by single-crystal XRD and with data of frozen solu-
tion EPR spectra (see for example, Figure 9). In most
of the complexes depicted in Figure 9 the ligands L
have donor atoms resembling those available in HTF,
namely in its iron binding sites. Table SI-8.5-1 includes
EPR spectroscopy data for several distinct systems
containing VIVO-acac species, with data including
either [VIVO(acac)2(L)] complexes (e.g. with L = Mepy
or py)[51] or [VIVO(acac)(L)] (e.g. with L = bzpy-tch[6] (4)
and sal-dmen (6),[92] Figure 9), where the spin Hamil-
tonian parameters are quite similar, some of them involving
the acac@ ligand with one of the Oacac donor atoms bound cis
to the Ooxido.
Considering complexes [VIVO(acac)2(4-Phpy)] (3) and
[VIVO(acac)2(py)] (9), while the DFT calculated energies of the
trans- and cis-isomers in MeOH solution are similar (the cis-
isomer is more stable than the trans-one by 3.3 and
7.5 kJ mol@1, respectively), their corresponding theoretical Az
values are also almost identical, that is, 160.6 V 10@4 (3-trans),
161.2 V 10@4 cm@1 (9-trans), 159.5 V 10@4 (3-cis) and 159.7 V
10@4 cm@1 (9-cis). These values are lower by &4 % than those
observed experimentally for the system bearing [VIVO(acac)2]
and pyridine (165.5 V 10@4 cm@1,[51] Table SI-8.5-1), the latter
being closer to the Az value of the penta-coordinated complex
[VIVO(acac)2] (165–168 V 10
@4 cm@1, Table 3). The calculations
also suggest that the coordination of Phpy or py to
[VIVO(acac)2] is not favorable thermodynamically, being both
Table 3. Spin Hamiltonian parameters obtained for the systems VIVOSO4 and apoHTF
and [VIVO(acac)2] and apoHTF in this work and in previous publications. The present
data were obtained by simulation of the experimental EPR spectra with the computer
program of Rockenbauer and Korecz.[90]







cies[26, 29, 30, 32, 84, 88, 89, 91]
A 1.938:0.002 168.5:0.5






























































































1.984 1.956 58.7 167.4
[a] EPR spectra of frozen solutions of [VIVO(acac)2] containing 2 % of ethylene glycol
(EtGlycol) or 4-10 % of DMSO are identical. [b] The EPR spectra of frozen solutions con-
taining [VIVO(acac)2] and apoHTF in the presence or absence of carbonate are identical
(see Figure SI-5-1).
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endothermic (by &21 kJ mol@1) and endergonic (by 70.7–
74.9 kJ mol@1).
Comparison of the data included in Tables 3 and SI-8.5-
1 allows stating that, the assignment of a particular formula-
tion or concluding the non-formation of VIVO-acac-apoHTF spe-
cies, based on the solution EPR spectra measured for the
[VIVO(acac)2]—apoHTF system, cannot be made reliably. Other
techniques must also be used (e.g. CD, MS measurements, etc.)
and the conclusions made must be compatible with all experi-
mental results obtained.
The similarity of the spin Hamiltonian parameters of several
[VIVO(acac)2(L)] and [V
IVO(acac)(L)] complexes and the CD and
EPR spectra obtained for the [VIVO(acac)2]—apoHTF system
lead us to state that the formation of [VIVO(acac)(apoHTF)]-type
species appears quite plausible. Thus, the EPR spectra obtained
in this work may be considered compatible with the sugges-
tion made above, that a significant fraction of the complexes
formed in solutions of [VIVO(acac)2] and apoHTF correspond to
[VIVO(acac)(apoHTF)] species, such as the example depicted in
Figure 10 A, where the VIVO:acac molar ratio is 1:1 and the VIV
is bound to more than one chiral residue of apoHTF.
According to the data of Table 2, at least three VIVO centres
may bind to apoHTF. If two bind to residues of the two iron
binding sites (e.g. as the example of Figure 10 A), then it is
plausible that at least one [VIVO(acac)2] may be bound to
apoHTF at a side group of an available imidazole, amino or car-
boxylate moiety of HTF residues (see Figure 10, B-trans and B-
cis). The formation of these [VIVO(acac)2(apoHTF)] species re-
sembles that of the many [VIVO(acac)2(L)] complexes reported
in the literature, for example, 2–8 and 3 (Figure 2, 9 and 10A),
this by itself supporting the plausibility of their formation.
At this point it is also worth to mention that the immobiliza-
tion of [VIVO(acac)2] onto solid supports has been report-
ed[15, 95–97] and the binding established has been considered to
involve: (i) hydrogen bonding between the pseudo p system
of the acac@ ligand and the silanol protons of the supports,
and/or (ii) ligand-exchange with the formation of a covalent
bond between the V centre and an O-atom from the support,
(iii) interactions between the complex vacant orbitals and the
p electrons of the polymer benzene rings of polystyrene sup-
ports,[97] (iv) Schiff base formation by condensation between
the carbonyl group of the acac@ ligand and the free NH2
groups previously grafted onto the support’s surface.[95]
Namely, the immobilization of [VIVO(acac)2] onto silica nanopar-
ticles functionalized with 3-aminopropyltriethoxysilane (APTES)
was reported to involve a covalent bond of the N-amino atom
with the VIV centre, as depicted in Figure 11.[15] This grafted
complex was applied in the catalytic epoxidations and it could
be recycled and reused four times, with similar catalytic activity
and regioselectivity. This means that the bond established is
strong enough for the complex to remain attached to the solid
support.
Thus, whatever the correct formulation of these anchored
VIVO-acac species to solid supports, besides the VIVO-acac-
apoHTF species discussed above (probably bound to some of
the amino acid residues of Fe binding sites), the formation of
[VIVO(acac)2(apoHTF)] complexes most probably also occurs,
but correspond to weaker interactions. In these species, be-
sides the monodentate coordination of donor atoms of avail-
able imidazole, amino or carboxylate moieties of HTF residues,
probably several types of intermolecular interactions are also
operating, for example, hydrogen-bond formation.
The formation of a Schiff base between -NH2 of amino acid
residues, for example, a lysine, and acac ligands probably does
not occur, as no electronic transitions due to imine bonds
were detected in the range 300–400 nm; additionally, the
Gibbs free energy of the reaction depicted in Scheme 1 sug-
gests that the process might not be thermodynamically fa-
vored.
Figure 8. High field range of the 1st derivative EPR spectra of solutions of
[VIVO(acac)2] (black), or [V
IVO(acac)2] and apoHTF with 2:1 molar ratio (blue)
and 4:1 molar ratio (red), recorded at 77 K. The vertical lines are inserted to
better identify the position of the maxima. The full spectra are depicted in
Figure SI-5-3.
Figure 9. Several [VIVO(acac)(L)] complexes reported in the literature, some
of them with spin Hamiltonian parameters closely resembling (see Table SI-
8.5-1) those obtained for the VIVO-acac-apoHTF system. For compounds 5–8
single-crystal XRD molecular structures were determined.
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2.2.6. DFT calculations
To investigate the plausibility of coordination of the
[VIVO(acac)+] moiety to Tyr, Asp and His, the amino acid resi-
dues of the iron binding site of HTF, DFT calculations of the
model complexes [VIVO(acac)(T)(A)(H)]@ (1T),
[VIVO(acac)(T)2(A)]
2@ (2T) and [VIVO(acac)(T)2(H)]
@ (3T) (T = p-
EtC6H4O
@ , A = EtC(= O)O@ , H = 4-ethylimidazole) (Figure 12)
were carried out for water solution. Model complexes 1T simu-
late the binding of [VIVO(acac)+] to one tyrosine, one aspartate
and one histidine residues of apoHTF, while complexes 2T and
3T model the binding with two tyrosines and either one aspar-
tate or one histidine residues. For each type of complex, all
possible geometrical isomers were calculated (Figure 12). The
results indicate that the isomer 6 of model complex 1T, with
the mutual trans-position of A and H, is the thermodynamically
most stable one. For model complexes 2T, the most stable
one, isomer 3, bears two T ligands trans to each other. Finally,
for model complexes 3T, the most stable one, isomer 4, has
the H and one of the T model ligands in the mutual trans-posi-
tion. In all of these most stable isomers, one of the O-acac
donors is trans to the O-oxido ligand. Other isomers of each
type of model complexes are less stable by 3.3–25 kJ mol@1.
Figure 10. Sketches of types of binding of VIVO–acac species to apoHTF. A : binding of [VIVO(acac)+] to donor atoms of amino acid residues of apoHTF, belong-
ing or not to the iron binding sites (here amino acids of residues from the N-lobe are specified); B-trans : binding of a donor atom trans to O-oxido of
[VIVO(acac)2] ; B-cis : binding of a donor atom cis to O-oxido of [V
IVO(acac)2] . Atom X may be for example, an N-amino, N-imidazole or O-carboxylato. The inser-
tion of dashed lines emphasize that hydrogen bonds or p-type bonds may be established between VIVO-acac complexes and residues of apoHTF.
Figure 11. [VIVO(acac)2] immobilized of onto silica nanoparticles functional-
ized with 3-aminopropyltriethoxysilane (APTES), as indicated in ref. [15] .
Scheme 1. Scheme modeling the reaction of [VIVO(acac)2] with -NH2 of an
amino acid residue to form a Schiff base. The Gibbs free energy of this reac-
tion in CHCl3 solution calculated by DFT procedures is + 55.6 kJ mol
@1. The
DFT calculated EPR spectroscopic parameters Az, Ax and Ay for the complex
with Schiff base are 163.4, 58.5, 57.7 V 10@4 cm@1, respectively.
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The calculations also indicate that model complex 3T is ther-
modynamically more stable than 1T, the DGs value of the reac-
tion 1T + T!3T + A being @22.6 kJ mol@1. The stability of com-
plex 2T relative to 1T or 3T cannot be estimated with any rea-
sonable accuracy due to different overall charge of these spe-
cies. Note that in 1T-3T the ligands are not linked with each
other.
Taking into account the rather small energy difference of
various geometrical isomers, the binding mode of [VIVO(acac)+]
to apoHTF is conceivably controlled by the secondary structure
of the protein and intermolecular interactions with groups
from the protein, rather than by the thermodynamic stability
of a particular ligand configuration in the metal coordination
sphere. Noteworthy is the finding that in all these simulated
[VIVO(acac)(L1)(L2)(L3)] structures, those found more stable in-
volve one of the Oacac donor atoms bound axially. It should
also be emphasized that hydrogen bonds to for example, the
Ooxido or Oacac atoms may change significantly the relative ener-
gies and the Az values corresponding to calculated 1T-3T
model structures.
The calculated hyperfine coupling constants Az for the vari-
ous isomers of 1T-3T are in the range of 153.6–161.6 V
10@4 cm@1 (Figure 12) and they are lower than the values found
experimentally for the system [VIVO(acac)2] + apoHTF (Table 3).
However, in similar structures including one water molecule
bound equatorially, instead of for example, a O-Tyr donor
atom, the corresponding Az values increase by (3 to 6) V
10@4 cm@1 (Figure 13).
The calculated DHs values of the reactions: [V
IVO(acac)2] +
T + A + H!acac@+ 1T (isomer 6) and VO(acac)2 + 2T + H!
acac@+ 3T (isomer 4) are significantly positive (62.8 and
41.0 kJ mol@1, respectively) indicating that the formation of
complexes 1T and 3T from VO(acac)2 is thermodynamically un-
favorable. This again suggests that the binding of [VO(acac)+]
to apoHTF should be stabilized also by intermolecular H-bond-
ing rather than by simple coordination of T, A and H to the
Figure 12. Calculated structures of complexes 1T-3T. Gibbs free energies in water solution relative to the most stable isomer and Ax, Ay and Az values are indi-
cated.
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metal. These effects are not taken into account in the calcula-
tions corresponding to Figures 12 and 13, neither possible ef-
fects from rearrangement of the apoHTF conformation upon
binding of VO-acac species. In the next section these effects
are somewhat taken into account.
2.2.7. Modeling of the binding of VO-acac species to HTF




[VIVO(acac)(H2O)] , were optimized at the PM7 semi-empirical
level as implemented in MOPAC2016[98, 99] and were checked
against B3P86/6–311 g DFT geometries.[100] The N-lobe of HTF
was modelled using (a) the closed conformation (PDB ID
1a8e),[101] (b) the oxalate-bound conformation (PDB ID 1ryo)[102]
(3), which is not as tightly packed around the iron site as the
closed conformation, as well as using (c) the open conforma-
tion (PDB ID 1bp5);[103] in the latter, the V atom was located at
the geometric centre of the iron-coordinating residues (see ex-
perimental and SI sections).
No meaningful structures of VIVO-acac complexes with the
closed conformation of HTF (after removing the FeIII and car-
bonate ions) were found due to the small volume available to
bind these complexes. For the other protein forms, the most
energetically favourable protein complexes were formed with
the [VIVO(acac)(H2O)2] species. For the association of all V
IVO
complexes, after re-optimization of protein conformation, com-
puted heats of formation with the open form of the protein is
always energetically preferred when compared with the associ-
ation with the oxalate-bound form. Table SI-10-1 includes the
computed heats of formation for the various systems before
carrying out the re-optimization of protein conformation. Table
SI-10-2 includes these data after the re-optimization. Globally,
it may be stated that the binding of either [VIVO(acac)+] or
[VIVO(acac)2] correspond to favourable thermodynamic process-
es, but it should be noted that in these calculations entropy
changes are not taken into account.
The modelling of the binding of the [VIVO(acac)+] moieties
correspond to lower computed heats of formation than those
for the binding of [VIVO(acac)2] . In each structure refined the
VO-acac complexes are tightly held in place by a large range
of interactions, including water bridges, hydrogen bonds and
metal cation-p interactions. Additionally, the processes where
the lower energies were obtained gave rise to a type of bind-
ing of vanadium to a tyrosine residue which was not anticipat-
ed. In fact, in the structures refined, apart from the V = O bond
lengths of ca. 1.6–1.7 a, and the binding to two O-acac atoms
at ca. 1.7–1.8 a, the VIV is bound to the aromatic ring of a tyro-
sine, with V-C distances in the 2.30–2.40 a range, resulting in
half-sandwich complexes; this type of binding has been found
for vanadocene(IV)-type compounds[105, 106] (see more details in
the SI section, namely Figures SI-10-1, -2 and -3). Coordinating
residues, and other relevant residues in the vicinity of the li-
gands, involve the Fe-binding residues, Asp63, Tyr95, Tyr188,
and His249, but also other protein residues, in particular
Lys206, Ser125, Ala126 and Pro247, also participate in the
ligand-protein interaction, which is in agreement with previous
results on the VO interaction with the N lobe of hTF in the
presence of carbonate.[104] However, the Az values calculated
for the model structures, upon freezing its coordinates similarly
to what was done in [104] are rather low, ca. 141 V 10@4 cm@1,
so we rule out this type of binding of VIVO-acac species.
The structure (model A, Figure SI-10-4) where in equatorial
position are O-acac (at 1.9 a), two O-atoms from Tyr188 (O at
1.9 a) and Tyr95 (HO at 2.5 a), O-carboxylate from Asp63 at
(2.0 a), and O-oxido and another O-acac axially, at 1.6 and
2.2 a, respectively, correspond to Az = 162 V 10
@4 cm@1, thus not
far from experimental. The water molecule in the vicinity is at
a 2.4 a V-Owater distance and there is a hydrogen bond between
the NH3
+ of Lis296 and the O-oxido (H-O distance of 1.9 a).
We are not stating that this particular structure (model A) is
the one formed in the system: N-lobe of apoHTF +
[VIVO(acac)2] , but instead that the binding of V
IVO(acac)+ moi-
eties to residues of the Fe-binding site can be modelled, the
reaction corresponding to this process is thermodynamically
favoured and may yield structures with Az values not far from
those of [VIVO(acac)2] complexes.
2.2.8. Fluorometric assays
Intrinsic protein fluorescence is mainly due to tryptophan and
tyrosine residues. Fluorescence assays have been used to mon-
itor the binding of several compounds to proteins, namely to
HTF and HSA. The study of the binding of [VIVO(acac)2] to BSA
by fluorometric measurements was reported before,[39] but not
to HSA.
Tryptophan residues are the least common amino acids in
proteins but normally dominate their fluorescence proper-
Figure 13. Calculated structures and spin-Hamiltonian parameters for some of the complexes of Figure 12, substituting equatorially bound O-Tyr donor
atoms, by Owater donor atoms.
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ties,[107–109] and are the most commonly used intrinsic fluoro-
phores. The fluorescence emission from Trp residues is very
sensitive to changes in local environment[110] and this sensitivi-
ty has been used extensively to monitor numerous biological
processes. However, often it is not possible to pinpoint the
precise causes of changes in the fluorescence yield, thus limit-
ing the usefulness of the fluorometric measurements. If there
is more than one Trp in a protein, as is the case of HTF, further
complications arise when trying to interpret the changes in
fluorescence at the molecular level. However, it was reported
that emission from the N-lobe of HTF is dominated by
Trp264.[108]
Except one study with vanadocene dichloride,[111] to our
knowledge fluorometric techniques were not previously re-
ported for studies of binding of vanadium compounds to HTF.
The binding of VIVO-complexes to apoHTF, namely at the iron
binding sites, leads to the presence of the VIVO-species not far
from a Trp residue at each site; moreover, the hydrodynamic
volume of the protein may change. Both these effects may
change the fluorescence intensity.
Figure 14 depicts fluorescence emission spectra of the
apoHTF-[VIVO(acac)2] system, when using the excitation wave-
length (lex) of 295 nm. ApoHTF demonstrates strong fluores-
cence emission with a maximum at &322 nm. As the complex
concentration increases the HTF fluorescence decreases; thus,
the fluorescence quenching is concentration-dependent and
apparently [VIVO(acac)2] binds close enough to the tryptophan
residues, namely Trp264, to quench their fluorescence. Under
our experimental conditions, no fluorescence emission in the
range 295–550 nm was displayed for the studied compounds
and therefore there was not any interference with the fluores-
cence of apoHTF.
It is common to use fluorescence quenching measurements
to evaluate binding constants of compounds to proteins. In
the case of organic compounds, the conditions required for
such methods to be reliable for use for this purpose have
been discussed.[112, 113] If these conditions are nor fulfilled, fluo-
rescence quenching measurements should not be applied to
evaluate binding constants of compounds to proteins, but in
practice many studies are published without verifying the val-
idity of the procedures. In the case of metal complexes there
are further requirements that will be discussed below.
The methodology typically used in many publications was
used in this work and is described in the SI section (SI-6) ;
namely the fluorescence quenching measurements were made
with a concentration of protein (apoHTF) of ca. 10@6 m, and
varying the metal complex concentration from ca. ca. 10@6 to
ca. 10@5 m (see Figure 14).
Upon applying the Stern–Volmer equation the correspond-
ing quenching constant KSV was obtained (Table 4). Following
the typical calculation methodologies used in the literature,
the quenching mechanism was considered to be static (due to
binding of a VO-acac complex to apoHTF) and the binding
constant KBC given by equation 4, and number of binding sites
(n) were determined (Table 4).
n ½VIVOðacacÞ2Aþ protein Ð f½VIVOðacacÞ2Agn-protein ð4Þ
When excitation was made at 280 nm (for which the other
protein fluorophores, Phe and Tyr, may also be excited)
a higher quenching % was obtained (45 %), as well as a higher
KSV constant (3.9 V 10
4 m@1). The calculated binding constant
was: KBC = 1.4 V 10
4 m@1.
Considering the procedure described above and in the SI
section (SI-6), from the fluorescence measurements we would
conclude that [VIVO(acac)2] is able to bind apoHTF, although
the quenching of the fluorescence is only moderate. Around
30 % quenching of the Trp fluorescence is observed, the KSV
being 1.9 V 104 m@1, the binding constant KBC estimated in these
measurements being 1.0 V 104 m@1.
Comments to the use of fluorescence quenching measurements
to calculations of binding constants. The fluorescence and its
quenching is a rather indirect measurement of the interaction
of [VIVO(acac)2] with apoHTF, as the Trp residues may not be
close to the binding site responsible for the quenching effect,
and there might be binding at sites which do not affect the
fluorescence emission. Moreover, in the case of metal com-
plexes, besides the requirements discussed in [112, 113] for the
validity of use of fluorescence emission to calculate binding
constants, there are further aspects/issues related to the speci-
ation of the systems at low concentrations of labile metal com-
Figure 14. Variation of the fluorescence intensity of apoHTF upon addition
of [VIVO(acac)2] . The apoHTF concentration was 1.02 V 10
@6 m and that of
[VIVO(acac)2] was increased from 0 to 1.77 V 10
@5 m, that is, from
[VIVO(acac)2]:HTF: ratios from 1 to 17. Conditions: T = 298 K, pH 7.4 (buffer)
and lex = 295 nm. Concentration of the mother solution of [V
IVO(acac)2]
added: 188 mm.
Table 4. Stern–Volmer constant (KSV), R
2 (from SV plot), binding constant
(KBC), number of binding sites on the protein (n) and R
2 (from KBC fitting)
for the interaction of [VIVO(acac)2] with HTF and HSA (see below).
Protein 10-4 KSV(M
@1) R2 10@4 KBC(M
@1) n R2
HTF 1.9 0.993 1.05 1.15 0.995
HSA 3.7 0.952 0.023 0.61 0.977
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plexes to which some attention should be given and are now
discussed.
Figure 3 depicts a speciation diagram calculated for total
VIVO and acetylacetone concentrations of 2 and 4 mm, respec-
tively. It is clear that in the pH range 6–8 [VIVO(acac)2] is the
main VIV-complex present in solution. However, if the concen-
tration of [VIVO(acac)2] is ca. 2 mm, close to the concentrations
used for the fluorescence quenching measurements in the sys-
tems [VIVO(acac)2] + apoHTF (and [V
IVO(acac)2] + HSA), the rela-
tive importance of most VIV-species differs (see Figure SI-7-2).
Namely, at pH 7.4 there are almost no [VIVO(acac)+] or
[VIVO(acac)2] species in solution. At these low [V
IVO(acac)2] con-




Considering the system [VIVO(acac)2] + apoHTF (or HSA) and
the conditions used in the fluorescence quenching measure-
ments in Figure 14 (apoHTF (1 mm) and [VIVO(acac)2] , varying
the [VIVO(acac)2] concentration from 1 V 10
@6 m up to 10 V
10@6 m, at pH 7.4), and taking the binding constant of
[VIVO(acac)2] to apoHTF (KBC = 10
4) obtained from the fluoro-
metric measurements (Table 4), it is clear in Figure 15 that no
VIVO-acac-apoHTF species exist in significant concentration.
Thus, any effects observed on the fluorescence spectra are not
due to VIVO-acac-apoHTF species formed, but instead to the
formation of [VIVO(apoHTF)] and [(VIVO)2(apoHTF)] complexes.
It is thus concluded that the methodology used above lead-
ing to the values presented in Table 4 is not valid to determi-
nate the binding constants of [VIVO(acac)2] to apoHTF or to
HSA. This conclusion may probably be equally applied to many
other labile (and hydrolysable) metal complex—protein sys-
tems previously reported with binding constants determined
by fluorescence quenching measurements. We do highlight
that researchers should carefully check which species may be
present at low protein and metal concentrations before apply-
ing these methodologies.
Even if a binding constant KBC of 10
12 is used for this system,
possibly much higher than would be reasonable to expect, the
speciation obtained (see Figure SI-7-3) indicates that in the
conditions used for the fluorescence quenching measure-
ments, it would also be not valid to apply the above
mentioned methodology; in fact, in this case there would
be at least 3 species contributing to the quenching of the
fluorescence: [VIVO(apoHTF)] , [(VIVO)2(apoHTF)] and
[VIVO(acac)2(apoHTF)] , not simply the last one.
2.3. Interaction of [VIVO(acac)2] with human serum albumin
2.3.1. Circular dichroism and EPR spectroscopies
As mentioned above, the binding of [VO(acac)2] to BSA was
studied by ITC and fluorescence spectroscopy.[2, 39] Namely, it
was reported that a 1:1 adduct is formed between [VIVO(acac)2]
and bovine serum albumin (BSA), with dissociation constants
(Kd) of 2.6 V 10
@7 (ITC) and 6.1 V 10@7 (fluorescence),[39] these cor-
respond to binding constants (1/Kd) of 3.8 V 10
6 and 1.6 V 106,
respectively; this was considered an important factor for its
biological activity in vivo, particularly its insulin-enhancing
effect.[2]
The binding of VIVO2 + to human serum albumin was studied
by several techniques, namely by EPR and ENDOR spectroscop-
ies,[27, 38, 44, 89, 115, 116] CD and visible absorption.[116] The results
show that VIVO occupies two types of binding sites in HSA; in
one of the sites the resulting VIVO-HSA complex has a weak CD
signal in the visible and its EPR spectrum may be easily mea-
sured; this was assigned to amino acid side chains of the
amino terminal site, Asp-Ala-His-, known as ATCUN site.[116] The
other binding site depicts stronger signals in the CD in the visi-
ble range, but has a hardly measurable EPR spectrum; it was
assigned as involving residues of the multi metal binding site
(MBS) of HSA.[116] Studies with fatted and defatted albumin
showed[116] that the binding of fatty acids decrease the ability
of VIVO to bind albumin.
Figure 16 depicts CD spectra measured with solutions con-
taining [VIVO(acac)2] and defated HSA in the visible range. It is
not clear if De¼6 0 are obtained at all ; if yes, the bands are ex-
tremely weak. Even using higher [VIVO(acac)2]:HSA ratios no
clear bands were recorded. ZnII-complexes do not absorb radi-
Figure 15. Speciation diagrams for the system apoHTF (1 mm) and [VO(acac)2] , at pH 7.4, varying the total [V
IVO(acac)2] concentration (CVO) from 1 V 10
@6 m up
to 10 V 10@6 m (see text of SI section), and taking the binding constant of [VO(acac)2] to apoHTF obtained in the fluorescence quenching measurements
(KBC = 10
4) by applying the typically used methodologies. The binding constants of [VIVO(apoHTF)] and [(VIVO)2(apoHTF)] are from [31], are valid at pH 7.4. The
formation constants for the system VIVO2+ + acac are from [4] and the hydrolytic constants for VIVO2 + from [3, 25] . (a) Distribution of species containing VIVO,
(b) Distribution of species containing apoHTF.
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ation in the 400–1000 nm range and do not have unpaired
electrons; therefore they are both CD and EPR silent. The Zn2 +
ions bind strongly to the MBS binding site of HSA, so if any
VIVO-acac-HSA species binds at this site, if a ZnII salt is added
they will be removed from it.[116–118] Upon addition of ZnCl2 to
a solution of [VIVO(acac)2] and HSA with a molar ratio of 2, the
very weak bands apparently observed in Figure 16 in the 700–
900 nm range are no longer seen; this could suggest that Zn2 +
ions are substituting VIVO-acac species bound at the MBS site;
however, in all CD spectra the signal-to-noise ratio is so low
that no definite conclusion can be made. The EPR spectra of
solutions containing [VIVO(acac)2] and HSA are depicted in Fig-
ures SI-5-4 and -5, as well as those recorded upon additions of
a solution of ZnCl2 so that Zn
II :HSA molar ratios of 1 and 2 are
obtained. No clear difference may be detected in the EPR spec-
tra of the frozen solutions of [VIVO(acac)2] or [V
IVO(acac)2] and
HSA containing or not Zn2+ ions. If any VIVO-species were
bound at the MBS site before the addition of ZnCl2, the corre-
sponding amount was small.
Globally, we may conclude that the EPR and CD spectro-
scopic data do not clearly rule out or confirm the presence of
VIVO-acac species bound to HSA; if the binding takes place,
probably these correspond to [VIVO(acac)2(HSA)] complexes in-
volving monodentate coordination of an N-amino, N-imidazole
or O-carboxylate from amino acid residues of HSA, otherwise
much stronger CD spectra would be measured, as was the
case of VIVO-maltolato complexes.[117]
2.3.2. Use of size exclusion columns.
To further confirm the binding of [VIVO(acac)2] to HSA, similarly
to what was done above for apoHTF solutions containing HSA
(ca. 137 mm), and two different amounts of [VIVO(acac)2] were
prepared, corresponding to the molar ratios 2 and 5, and
eluted with tris buffer solution through desalting columns (PD-
10 size exclusion columns, see SI section); the eluates of the
first eluted fractions were analyzed by ICP-AES. The dilution
effect (&70 %) was determined taking into account the ab-
sorbance of an HSA solution before and after eluting it, in ex-
periments with no addition of [VIVO(acac)2] . Results of the ICP-
AES analysis are included in Table 2.
The binding of [VIVO(acac)2] to HSA is weak, thus it might
happen that part of the [VIVO(acac)2] initially bound to HSA
was lost during elution through the size exclusion column, but
clearly this data indicates that in solutions containing
[VIVO(acac)2]:HSA molar ratios of 5, not more (most probably
less) than one VIVO-(acac) moiety is bound to each protein mol-
ecule.
2.3.3. Fluorometry experiments
While BSA has two Trp residues, HSA has only one. The intrin-
sic fluorescence of HSA is mainly due to the Trp214 residue,
because of the very low quantum yield of the Phe and Tyr resi-
dues.[119, 120] When the excitation wavelength (lex) of HSA is se-
lected at 280 nm both Trp and Tyr residues contribute to the
fluorescence emissions. However, at lex = 295 nm, the emission
observed is only due to Trp214 which displays a strong fluores-
cence emission peak with lmax&330 nm.[119]
Under our experimental conditions, no fluorescence emis-
sion in the range 295–550 nm was displayed for the studied
compounds and therefore there was not any interference with
the Trp214 fluorescence of HSA. Figure 17 depicts fluorescence
emission spectra at lex = 295 nm of a solution of HSA (ca.
1 mm) and upon additions of a solution of [VIVO(acac)2] . Under
these conditions HSA has fluorescence emission with maxi-
mum intensity at &338 nm. As the [VIVO(acac)2] concentration
increases the HSA fluorescence decrease; thus the fluorescence
quenching is concentration-dependent and probably at least
Figure 16. CD spectra of solutions containing [VIVO(acac)2] and HSA (600 mm)
in PBS buffer of pH 7.4. HSA (black spectrum), [VIVO(acac)2]:HSA (2:1, immedi-
ately after addition of [VIVO(acac)2] , blue spectrum) and the same solution
after ca. 1 h (red). An optical path of 20 mm was used.
Figure 17. Fluorescence emission spectra measured for a solution of HSA
and upon adding [VIVO(acac)2] . The initial concentration of the HSA solution
was 1.03 V 10@6 m and that of [VIVO(acac)2] was increased from 0 to
1.53 V 10@5 m (from [VIVO(acac)2]:HSA ratios 1 to &15). Conditions: T = 298 K,
pH 7.4 and lex = 295 nm. The arrow indicates the [V
IVO(acac)2] concentration
increase. The concentration of the solution of [VIVO(acac)2] added was
&234 mm, and the maximum amount of DMSO present was &1.2 %.
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part of the bound [VIVO(acac)2] does it close to the Trp residue.
However, after addition of ca. 5 mole equivalents of
[VIVO(acac)2] , only &12 % quenching is observed and &21 %
after addition of &15 mole equivalents, Figure SI-6-4.
We followed a similar methodology to the one applied in
the [VIVO(acac)2]-apoHTF system, to obtain the Stern–Volmer
constant and a binding constant of [VIVO(acac)2] to HSA (see SI-
section), and the results are shown in Table 4. However, as ex-
plained above, this methodology is not reliable or valid to
obtain the binding constant in this system (and in many other
systems reported in literature), and we include this information
in this text to highlight this fact.
2.4. Human cells studies: intracellular distribution of
[VIVO(acac)2]
The cytotoxic activity of [VIVO(acac)2] was evaluated in the
A2780 ovarian cells within the concentration range 0.1–100 mm
using the colorimetric MTT assay. The complex presented mod-
erate cytotoxic activity with an IC50 = 66:18 mm, after 24 h in-
cubation with the cells (Figure SI-12-1).
The IC50 value (66 mm) was the concentration of [V
IVO(acac)2]
selected to carry out intracellular distribution studies. As de-
picted in Figure 18 more than 60 % of complex is retained in
the membrane, where large complexes of proteins act to carry
out vital cellular processes; this corresponding to ca. 18.5 ng of
V/ million A2780 cells. Only a small percentage was retained in
the nucleus, an interesting result taking into consideration the
complex remarkable nuclease activity of [VIVO(acac)2] using
plasmids (naked DNA).[20, 21]
Globally the total amount of vanadium analyzed by ICP-MS
in the A2780 ovarian cells after 24 h of incubation with
[VIVO(acac)2] is low (about 30 % or less of those of Cu and Zn
amounts found in the same study, carried out with other types
of complexes),[121] and more than 60 % is localized on its mem-
brane. The nature of the V-species present either in the mem-
brane or in each of the cells’ compartments is not known, and
probably the amount found in the nucleus is too low to affect
it.
The cells were cultured in RPMI supplemented with 10 %
fetal bovine serum (FBS), and exposed for 24 h to the complex.
Fetal serum albumin, is one of the major components of FBS,
and neither this protein nor HSA have specific binding sites for
vanadium, thus we would expect rather similar transport ca-
pacity. Thus, this study suggests (at least for the A2780 ovarian
cells), that albumins are not efficient transporters of
[VIVO(acac)2] , for its uptake inside the cells. However, the
amount of vanadium analyzed in the membranes is enough to
affect significantly their metabolism. It is known that for exam-
ple, membranes contain several types of relevant proteins, and
the binding of V-species may change/inhibit their biological
function.
3. Conclusions
[VIVO(acac)2] (1), is one of the most remarkable vanadium com-
pounds and found uses in multiple areas. Namely it has been
suggested as a prospective drug for the treatment of diabetes,
cancer and in tumor diagnosis. The understanding of how it is
transported in blood is of major importance to establish its
pharmacokinetics and pharmacodynamics.
Previous reports addressing the interactions between
[VIVO(acac)2] and plasma proteins are contradictory,
[2, 29, 43–45] but
have agreed in the conclusion that [VIVO(acac)2] does not bind
to human serum apotransferrin. In this work we report circular
dichroism and MALDI-TOF data that clearly confirms that VIVO-
acac species bind to human serum apo-transferrin. The EPR
spectra measured, SAXS data and DFT calculations corroborate
the plausibility of this conclusion.
Analysis of apoHTF and vanadium contents of samples con-
taining [VIVO(acac)2] and apoHTF upon elution through size ex-
clusion columns confirm that up to three VIVO-acac species
may bind to apoHTF. Similar studies carried out for the
[VIVO(acac)2]-HSA system did not confirm or rule out binding to
albumin, but the interactions of [VIVO(acac)2] are much weaker
with HSA than with apoHTF. For example, when using
[VIVO(acac)2]:HSA ratios of 5, significantly less than one vanadi-
um containing complex binds to HSA.
Previous reports[29, 43–45] on the non-binding of [VIVO(acac)2]
to apoHTF explained by the stability of [VIVO(acac)2] , or the ab-
sence of water molecules coordinated in the equatorial posi-
tion to be replaced by donor groups of amino acid residues, or
inability of this binding, are contradicted by the numerous pre-
vious reports of this type of binding in solution, by the several
Figure 18. V content in the A2780 subcellular fractions after 24 h exposure to the complex at a concentration equivalent to the IC50 value (66 mm). Results are
expressed as total vanadium accumulation in ng per million cells.
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reported molecular structures determined by single-crystal
XRD where such binding, forming either [VIVO(acac)2(L)] or
[VIVO(acac)(L)] complexes, have been confirmed. Additionally
there are several publications of [VIVO(acac)2] bound to solid
supports and used as heterogenized catalysts, further attesting
the plausibility of the formation of VO-acac-apoHTF com-
plexes.
DFT calculations with [VIVO(acac)(L1)(L2)(L3)] complexes,
where L1-L3 are models of His, Tyr and Asp residues, suggest
that the (Oaxial, Oequatorial) binding of acac
@ is preferred over the
(Oequatorial, Oequatorial) type of binding. Additionally, DFT calcula-
tions suggest that, besides the coordination bonds established,
probably the VO-acac-apoHTF species formed are stabilized by
intermolecular interactions with amino acid residues from the
protein. This is confirmed in modeling calculations of the bind-
ing of VIVO(acac)+ species to amino acids of the N-lobe of
apoHTF.
Speciation calculations done for solutions with low concen-
trations of apoHTF (ca. 1–2 mm) and of [VIVO(acac)2] (ca. from
1 to 17 mm), typical of fluorescence studies to evaluate the
binding of metal complexes to HTF or albumin, rule out the
possibility of using these methodologies to calculate the bind-
ing constants of [VIVO(acac)2] to these proteins. We predict that
similar conclusions may be extrapolated to many other com-
plexes involving labile and hydrolysable metal ions, particularly
those that bind strongly to serum proteins such as CuII, ZnII
and FeIII. Globally, these speciation considerations also indicate
that under physiological conditions, thus at low [VIVO(acac)2]
concentrations, ca. 10 mm or lower, most of the vanadium is
bound to transferrin as VIVO-[31, 32] or VIII-HTF[30, 33, 37, 122–124] species
without the original acac@ ligands. At higher [VIVO(acac)2] con-
centrations and equivalent amounts of apoHTF, our data indi-
cates that [VIVO(acac)+] moieties bind to apoHTF involving co-
ordination of VIV to some of the Fe-binding site residues.
If [VIVO(acac)2] is administered orally, certainly vanadium spe-
ciation in the gastrointestinal tract will change significantly
and most probably vanadium and acetylacetone will reach the
blood separately.[2, 17, 124] However, if the drug is administered
by injection (or encapsulated), [VIVO(acac)2] may then reach the
blood maintaining its integrity. In either case this would not
affect the final conclusions of the present study regarding the
binding of [VIVO(acac)2] to serum proteins.
In the intracellular distribution determination of [VIVO(acac)2] ,
evaluated in the human A2780 ovarian cancer cells at IC50 con-
centration (66 mm) for 24 h, the total vanadium up-taken is rel-
atively low (when compared to Cu- and Zn-compounds exam-
ined in the same cells) and &63 % of the vanadium analyzed
by ICP-MS was found in the membrane, &9 % in the nucleous,
&12 % cytoskeleton and &16 % in the cytosol. The incubation
medium in these studies also contained ca. 35 mM of fetal
serum albumin, thus we would expect rather similar transport
capacity as that of HSA“. Thus, this study suggests, at least for
the A2780 ovarian cells, that albumins are not efficient trans-
porters of [VIVO(acac)2] for its uptake inside the cells.
Experimental Section
4.1. Preparation of solutions
Millipore water was used for the preparation of solutions of the
complexes for studies and buffer solutions. The water was pro-
duced using a Mili-Q water purification system.
Buffer solutions. Almost all measurements were carried out in aque-
ous buffered media. Phosphate Buffered Saline (PBS) from Sigma–
Aldrich was used whenever stated: one tablet dissolved in 200 mL
of MilliporeS water yields 0.01 m phosphate buffer, 0.0027 m potas-
sium chloride and 0.137 m sodium chloride, pH 7.4, at 25 8C. Hepes
buffer. The composition of the Hepes buffer used is 50 mm Hepes
(Sigma–Aldrich), 25 mm carbonate added as NaHCO3 (Sigma–Al-
drich), 1 mm phosphate added as NaH2PO4·H2O (Merck) and
0.20 mm KCl (Merck). This buffer system was adjusted to a pH of
7.4 using concentrated KOH. The composition of the Tris buffer
used is 0.10 m Tris and 50 mm NaHCO3. This buffer system was ad-
justed to pH 7.4 using concentrated HCl.
Protein solutions. apoHTF (ATF2011-07; >95 %), was purchased
from AkronQ bio tech; fatty acid and globulin free human serum
albumin (Sigma Aldrich, A3782, +99 %), lyophilized powder with
a molecular mass of 67 kDa was used. Human apo-transferrin solu-
tions were prepared by dissolving the protein in buffer at pH 7.4.
The solutions were allowed to stand for at least 1 h to allow equili-
bration. During this period they were gently swirled without
strong agitation. The concentration of apoHTF solutions were de-
termined by measuring the absorbance at 280 nm using an extinc-
tion coefficient of 92 300 m@1 cm@1;[31, 125, 126] and for albumin it was
36 850 m@1 cm@1.[31, 127] Normally nitrogen gas was bubbled through
all solutions prior to use for measurements with VIV-complexes to
displace any oxygen that may be present.
[VIVO(acac)2] solutions. [V
IVO(acac)2] was purchased from Fluka
S Ana-
lytical. Stock solutions were freshly prepared by dissolution in
either DMSO or MeOH, and this was diluted in water or buffer for
further use. Normally the amount of organic solvent present in the
described experiments was 1–4 %.
4.2. Desalting procedure with size exclusion columns.
PD-10 Desalting Columns containing SephadexQ G-25 Medium,
a size exclusion packing, were purchased from GE Healthcare, and
used as recommended, namely the equilibration and elution pro-
cedures. Several [VIVO(acac)2]:protein (in tris buffer (0.10 m) contain-
ing Na2CO3 (2.5 V 10
@2 m) molar ratios were used. Solutions were al-
lowed to equilibrate for 10–20 minutes (under N2 atmosphere).
The dilution effect was determined by passing the protein samples
and measuring their absorption at 280 nm before and after elution.
In 5 mL volumetric flasks, to each protein solution (&1.4 V 10@4 m)
adequate volumes of [VIVO(acac)2] (ca. 3 V 10
@2 m) in DMSO were
added to obtain the desired [VIVO(acac)2]:protein ratios. The first
component to elute from these size exclusion columns is the pro-
tein, which may (or may not) contain bound vanadium-complexes.
The protein-metal solutions collected from these exclusion col-
umns were used to evaluate the vanadium content by ICP-AES,
using a Horiba Jobin–Yvon apparatus, model Ultima.
4.3. Spectroscopic and mass spectrometric measurements
Ultraviolet-visible absorption spectroscopy. All UV/Vis absorption
spectra were recorded with PerkinElmer Lambda 35 spectropho-
tometer. Quartz SUPRASILS cells from HellmaS Analytics of either
1 mm, 2 mm, 10 mm or 20 mm optical path were used in the ex-
periments.
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Circular dichroism spectroscopy. CD spectra were recorded on
a Jasco J-720 spectropolarimeter either using the usual photomul-
tiplier (200–800 nm range) or with a red-sensitive photomultiplier
(EXWL-308) in the 400–1000 nm range. The measurements were
normally carried out at &25 8C using either a 20 mm (chamber
volume &5.0 mL) absorption cells from HellmaS , or a Macro Supra-
silS 3.5 mm I.D. V 50 mm cylindrical quartz cell (Jasco Parts Center,
CQ3-50, chamber volume &800 mL),[78] or a 2 mm cell (chamber
volume &600 mL) made of Quartz SuprasilS from HellmaS Analytics.
Electron paramagnetic resonance (EPR) spectroscopy. The first deriva-
tive X-band EPR spectra of the frozen solutions (frozen in liquid ni-
trogen) were recorded on a Bruker ESP 300E spectrometer at 77 K.
The ESP 300E spectrometer was operated at &9.51 GHz with a fre-
quency modulation of 100 KHz. The samples (250 mL) were placed
in 3 mm quartz tubes (Wilmad 707-SQ-250M) and frozen in liquid
nitrogen. The calibration of the magnetic field frequency was done
using DPPH (2,2-diphenyl-1-picrylhydrazyl) as standard. While keep-
ing the resolution at 4096 points, the microwave power was ad-
justed to 20 dB and the receiver gain was set between 4.5 V 104
and 7.9 V 104. To improve the signal-to-noise ratio 5 to 10 scans of
each sample were accumulated.
Fluorescence spectroscopy. The fluorescence spectra were obtained
on a FluorologS Horiba Jobin Yvon Spectrofluorometer with single
proton counting controller—FluoroHub from Horiba ScientificQ .
The samples were excited either at the wavelength of 280 nm (slit
width 5 nm) and the emission spectra were measured in the 290–
500 nm range, or at 295 nm (slit width 9 nm) with the emission
spectra measured in the 305–515 nm range. All measurements
were done in 10 mm fluorescence quartz cells from HellmaS Analyt-
ics with the chamber volume of &3.50 mL at room temperature.
Electrospray mass spectrometry (ESI-MS). A 500-MS Varian Ion Trap
Mass Spectrometer was used to measure ESI-MS spectra of solu-
tions in both positive and negative modes. The mass spectrometer
was operated in the ESI negative or positive ion mode, typically
with the following optimized parameters: ion spray voltage,
@4.5 kV; capillary voltage, @20 V; tube lens offset, @124.99 V,
sheath gas (N2), 20 arbitrary units (negative mode); ion spray volt-
age, 5 kV; capillary voltage, 5 V; tube lens offset, 63 V, sheath gas
(N2), 20 arbitrary units (positive mode); capillary temperature,
275 8C. Spectra typically correspond to the average of 20–35 scans,
recorded in the range between 100–600 Da.
Matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI-TOF). Mass spectra were obtained using a Bruker
Daltonics Ultraflex MALDI TOF/TOF Mass Spectrometer operating
in linear mode with positive ion extracting at 25 000 V and
a pulsed ion extraction of 480 ns. Each final spectrum was the ac-
cumulated result of at least 1000 laser shots that were obtained
from 10 different manually selected regions of the same sample,
over a range of 14 000–100 000 Da. Prior to calibration, the spectra
were processed with Compass 1.3 using smoothing and baseline
subtraction for reproducible peak annotation. The spectra were ex-
ternally calibrated using of 50 pmol of albumin from bovine serum
([M+H]+ 66,430).
4.4. Small Angle X-ray Scattering (SAXS)
4.4.1. Sample preparation
Human serum apo-transferrin (apoHTF), from Sigma–Aldrich, was
dissolved (20 mm Tris-HCl pH 8, 20 mm sodium carbonate and
200 mm sodium chloride) to a concentration of 6 mg mL@1. A first
sample of native apoHTF (500 mL) was then passed through a PD-
10 MiniTrap G-25 column according to the previously reported pro-
cedure.[26] A second sample of apoHTF (500 mL) was incubated with
a 30 times molar equivalent excess of [VIVO(acac)2] at room temper-
ature; after one hour of incubation, the excess of unbound ligand
was removed using PD-10 MiniTrap G-25 column. In both samples,
a final protein concentration of 3 mg mL@1 was obtained for a 1:2
diluted sample.
4.4.2. Data collection and processing
The two samples, native apoHTF and apoHTF-[VIVO(acac)2] , were
analyzed by SAXS immediately after passing through PD-10 Mini-
Trap G-25 columns. SAXS data were collected at beamline BM29
(ESRF, Grenoble, France) using a robotic sample changer.[128, 129] Ten
frames of one second each were collected and all the measure-
ments were done at 277 K. Different protein concentration ranges
were used: 3 to 0.19 mg mL@1 for both samples. Data were re-
duced and analyzed using Scatter (Diamond Light Source, UK) and
the ATSAS suite.[80] Each experimental frame was inspected for radi-
ation damage; these frames were removed from further consider-
ation and not used for buffer subtraction. Theoretical SAXS curves
were calculated using CRYSOL.[82] Real space inversion obtain the
P(r) function (pair distance distribution function) was carried out in
Scatter. The P(r) function is the Fourier transform of the scattering
pattern, and represents a histogram distances between all possible
pairs of atoms in a structure. An ensemble of seven low resolution
envelope models were generated from the P(r) function in
DAMMIF,[130] and then subject to averaging and filtering with DAM-
AVER and DAMFILT.[131] The output from DAMFILT was then passed
to DAMMIN as a start model for final refinement against the exper-
imental curve. Other details are given in the SI section (SI-9).
4.5. Spectroscopic studies with solutions of [VIVO(acac)2] and
monodentate ligands
4.5.1. Absorption spectra of solutions of [VIVO(acac)2] and
monodentate ligands
For these studies an aqueous solution of NaHCO3 was prepared
and a controlled volume of HCl (1.0 m) was added, so that the total
carbonate concentration is 40 mm and the pH 6.2, and the solution
was degassed. Stock solutions of each monodentate ligand: imida-
zole, 2-Me-imidazole, benzimidazole, pyrazole, 4-t-buthylphenol,
were dissolved in this aqueous buffered solution in separate 5 mL
volumetric flasks. The solutions were degassed and an accurately
measured volume of a freshly prepared solution of [VIVO(acac)2] in
MeOH (ca. &76 mm) was added to ensure a final concentration of
&2.0 mm in each of the four 5 mL volumetric flasks. The MeOH %
was kept constant at 2.7 % in the final 5.0 mL solutions. The li-
gands, except the 4-tert-butylphenol, were dissolved in the aque-
ous buffer medium as stock solutions. Again the proper volume of
buffer was added to the 5 mL volumetric flask in order to obtain
ratios L:[VIVO(acac)2] of 0:1, 1:1, 2.5:1 and 5:1. The 4-tert-butylphe-
nol (not adequately soluble in water) stock solution was prepared
in MeOH; the amounts of [VIVO(acac)2] and solutions of ligands
were then controlled in order to keep the % of organic solvent
below 5 % and a constant concentration of metal complex of
2.0 mm. The ratios of L:[VIVO(acac)2] were 0:1, 1:1, 2:1 and 4:1. The
two last ratios (with larger amount of the ligands) lead to some
precipitation inside of the container. The initial pH of the
[VIVO(acac)2] solution was 7.0:0.2. Upon addition of the ligands
the pH values decreased 0.3–0.4 pH units on going from 0:1 to the
4:1 ratios. The absorption spectrum of each of these solutions was
measured in the range 380–900 nm, the measurement starting
always after the same period of time upon preparing each solu-
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tion. Samples were also similarly prepared with lactic acid, but no
buffer was added and the pH was adjusted to 6.0 with solutions of
HCl or NaOH. Both visible absorption and CD spectra were record-
ed (section SI-8.4).
Additional details of preparation of solutions are given in the SI
section.
4.5.2. Mass and EPR spectra of solutions of [VIVO(acac)2] and
monodentate ligands
A stock solution of [VIVO(acac)2] (80 mm) was prepared in methanol
(previously degassed with N2). Stock solutions of several monoden-
tate ligands (imidazole, methylimidazole, benzimidazole, pyrazole
and phenol) were prepared in 10 mm NH4CH3COO aqueous solu-
tion (previously set to pH 6.5). All these solutions were degassed
with N2. Accurately measured volumes of each solution of mono-
dentate ligand and of the NH4CH3COO aqueous solution were
added to six distinct vials using micropipettes, and an accurately
measured volume of [VIVO(acac)2] in methanol was added to each
of the six flasks. After the addition of [VIVO(acac)2] the solutions
were purged with a gentle flow of N2 gas for about 1 minute. Final
solutions are 1.1 mm in [VIVO(acac)2] and &2 % v/v MeOH. The
molar ratio VIVO:ligand is 1:7 in all samples and pH values range
from 6.58 to 7.15. Additional details are given in the SI section.
For each of the six solutions, ESI-MS (+ /-) was carried out ca. 5 mi-
nutes after the addition of [VIVO(acac)2] . Samples of these solutions
were also introduced in tubes (for EPR spectroscopic measure-
ments) and immediately frozen in liquid N2.
4.6. Maldi-TOF spectrometric measurements
Sample preparation. [VIVO(acac)2] stock solutions were prepared in
MeOH with ca. 3 mm immediately before mixing. Solutions of
apoHTF from PROSPEC were prepared with ca. 300 mm by dissolv-
ing the protein in NH4HCO3 buffer (pH 7.4, 25 mm). These solutions
were allowed to stand overnight to allow equilibration.
Samples for MALDI-TOF MS were prepared with
[VIVO(acac)2]:apoHTF molar ratios of 0:1, 1.1, 1:2, 3:1 and 5:1 by
mixing different volumes of the stock solutions with buffer. The %
of organic solvent was <8 % (v/v) and the apoHTF final concentra-
tion was either 50 mm (two sets of experiments, or 100 mm (one set
with = 0:1, 1.1, 2:1 and 3:1 [VIVO(acac)2]:apoHTF molar ratios). The
dried Droplet preparation procedure was used:
Dried Droplet preparation. 2 mL of each sample was mixed with
2 mL of matrix solution (saturated solution of sinapinic acid in 1 mL
of 30 % (v/v) acetonitrile and 0.1 % (v/v) aqueous trifluoroacetic
acid). Then 1 mL of the sample-matrix solution was deposited by
duplicate onto a MTP 384 ground steel BC target and allowed to
dry at room temperature. The apoHTF concentration of the final
samples was thus 25 mm.
In one set of experiments two spots were deposited, very close to
each other but without contact (at less than ca. 0.5 mm): one con-
taining the apoHTF, the other containing a solution of [VIVO(acac)2]
(see also the SI section). The laser shots were done in a zigzag
fashion so that both spots were included. In this way it was possi-
ble to check if the formation of [VIVO(acac)2]:apoHTF species could
be formed in the gas phase, thus giving false positives. The m/z
peaks obtained in these experiments were equal to those of
apoHTF alone, therefore the existence of false positives can be
ruled out (or at least the probability of their existence extremely
low).
4.7. Human cells studies; intracellular distribution of
[VIVO(acac)2] .
The intracellular distribution of [VIVO(acac)2] was evaluated in the
human A2780 ovarian cancer cells. For the assays cells (~1 V 106/
5 mL medium) were cultured in RPMI supplemented with 10 %
fetal bovine serum (FBS) and exposed to the complex for 24 h
(37 8C, 5 % CO2 and humidified atmosphere) at a concentration
equivalent to the IC50. The IC50 was obtained from a dose-response
curve using the MTT cytotoxicity assay. The culture conditions and
procedures were similar to previously described methods.[132] After
incubation cells were washed with PBS and centrifuged to obtain
a pellet; the subcellular soluble protein fractions i.e. , cytosol (pro-
teins from cytoplasm), membrane/particulate (membrane proteins
including organelles), nuclear fraction (nuclear proteins, including
the nuclear membrane proteins) and the cytoskeletal fraction (in-
soluble proteins and genomic DNA) were extracted using a cell
fractionation kit FractionPREPQ (BioVision) following the manufac-
turer’s recommended procedures.
Each cellular fraction was digested with 0.5 mL of distilled conc.
HNO3 in a closed pressurized microwave digestion unit (Mars5,
CEM) for 12 h at 150 8C in HP500 vessels and then diluted in ultra-
pure water to obtain a 2.0 % (v/v) acid solution. The vanadium con-
tent was measured using a Thermo XSERIES quadrupole ICP-MS in-
strument (Thermo Scientific). The instrument was calibrated using
a multi-element ICP-MS 71 C standard solution (Inorganic Venture).
Indium-115 (10 mg L@1) was used as the internal standard.
4.8. DFT calculations.
The full geometry optimization of the molecular structures was car-
ried out at the DFT level of theory using B3P86 functional[133, 134]
with the help of the Gaussian 09 program package.[135] This func-
tional was found to be appropriate for the theoretical studies of
structural parameters and 51 V NMR chemical shifts of various V
complexes.[92, 93, 136] The optimization was carried out taking into ac-
count solvent effects using the IEFPCM solvation model[137, 138] with
the UAKS molecular cavity and dispersion, repulsion and cavitation
contributions. Water or methanol was used as solvent. No symme-
try operations were applied for any of the structures calculated.
The geometry optimization was carried out using a relativistic
Stuttgart pseudopotential which describes 10 core electrons and
the appropriate contracted basis set (8s7p6d1f)/[6s5p3d1f] for the
vanadium atom[139] and the 6-31G* basis set for other atoms. The
Hessian matrix was calculated analytically for all optimized struc-
tures to prove the location of correct minima (no imaginary fre-
quencies) and to estimate the thermodynamic parameters, the
latter being calculated at 25 8C.
The single point calculations at the IEFPCM-B3P86/6-311 + G**
V(ECP)//6-31G* V(ECP) level of theory were then carried out. The
basis set corrected enthalpies and Gibbs free energies in solution
(Hs and Gs) discussed in the text, were calculated using the follow-
ing equations:
Hs ¼ Esð6-311þ G* *Þ@Esð6-31G*Þ þ Hsð6-31G*Þ ð5Þ
Gs ¼ Esð6-311þ G* *Þ@Esð6-31G*Þ þ Gsð6-31G*Þ ð6Þ
The 51 V hyperfine coupling constants were estimated in gas phase
at the single-point calculations using the BHandHLYP functional
and 6–311 + G** basis set for all atoms on the basis of the equilibri-
um geometry obtained at the IEFPCM-B3P86/6-31G*(V-ECP) level of
theory. The anisotropic 51 V hyperfine coupling constants Ax, Ay,
and Az were estimated as the sum of the isotropic Fermi contact
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term and corresponding dipolar hyperfine interaction term.[140]
Wave functions were verified for their stability using the keyword
STABLE in Gaussian. If necessary, they were reoptimized to achieve
a stable solution.
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